Startup profile · funding coverage
Erasca
Clinical-stage oncology company developing therapies that shut down multiple cancer growth pathways simultaneously.
Stage
public
Status
public
Coverage
full
Why Erasca is interesting
Founded by Ignyta alum Jonathan Lim, Erasca raised one of 2020's largest biotech rounds ($200M Series B) to pursue multi-pathway cancer drugging beyond single-target bets, then listed on NASDAQ as ERAS in 2021.
Key facts
- Series B (Apr 2020): $200M co-led by ARCH Venture Partners (/fund/arch-venture-partners) and Cormorant Asset Management
- IPO (Jul 2021): Listed on NASDAQ as ERAS
- Thesis: multi-pathway oncology drugging targeting RAS/MAPK and related cancer signaling
Investors in our directory
Funds linked from Erasca's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Erasca's financing or category context.
FAQs about Erasca
Funding context and why this company shows up in venture coverage.
Erasca is a clinical-stage biotech developing oncology therapies that target multiple cancer growth pathways, with a focus on shutting down RAS/MAPK signaling networks.
Erasca's $200M Series B was co-led by ARCH Venture Partners (/fund/arch-venture-partners). Andreessen Horowitz (/fund/andreessen-horowitz) is also listed among its backers.
Erasca went public on NASDAQ (ticker ERAS) in July 2021 after its Series B. It is now a publicly traded biotech company.
It bets that shutting down multiple cancer pathways simultaneously can succeed where single-target drugs fail — a thesis backed by one of 2020's largest private biotech rounds.
Erasca is public. It trades on NASDAQ under the ticker ERAS.
Last updated: 2026-07-24